Type 2 Diabetes Mellitus (T2DM)NCT06852950
Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
A study testing Libre 3 Plus Continuous Glucose Monitor and Dexcom G7 Continuous Glucose Monitor in people with Type 2 Diabetes Mellitus (T2DM) and Type 1 Diabetes Mellitus (T1DM), run by Vanderbilt University Medical Center at 1 site in United States.
Trial summary
This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type 2 Diabetes Mellitus (T2DM), Type 1 Diabetes Mellitus (T1DM), Hyperglycemia
- What is being tested?
- Libre 3 Plus Continuous Glucose Monitor and Dexcom G7 Continuous Glucose Monitor
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Mar 2025to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
- Able to give informed consent
- Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
- POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
- Need glucose readings greater than or equal to one time per day
- Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone
Who cannot join
- Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
- Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
- Received chemotherapy during current hospitalization
- Planning on major surgery within 10-15 days
- Hemodialysis or peritoneal dialysis
- Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
Show all 12Show fewer
- Vitamin C use of more than 500 milligrams per day
- Hydroxyurea use
- Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
- Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
- Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
- Skin allergy to adhesives
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
Angel Morvant, MD, (615) 343-8332, angel.morvant@vumc.org
Angel Morvant, MD
About this study
This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.
- Being tested
- Libre 3 Plus Continuous Glucose Monitor, Dexcom G7 Continuous Glucose Monitor
- Medical subject headings
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Libre 3 Plus Continuous Glucose MonitorDevice
Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
Dexcom G7 Continuous Glucose MonitorDevice
Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
| Study group | Role | What they receive |
|---|---|---|
| Libre 3 Plus Continuous Glucose Monitor | Experimental | Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor. Receives: Device: Libre 3 Plus Continuous Glucose Monitor |
| Dexcom G7 Continuous Glucose Monitor | Experimental | Subjects in this arm will start using the Dexcom G7 continuous glucose monitor. Receives: Device: Dexcom G7 Continuous Glucose Monitor |
What is being measured
The primary outcome is the main question the study is designed to answer.
Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system
Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system: regarding how do subjects feel that using CGM impacted their glucose control on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better?; regarding what is the overall opinion of subject's experience with CGM use on a scale of 1-5, with 1=very negative, 2=negative, 3=neutral, 4=positive, 5=very positive.
Measured: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care
Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care: regarding how do subjects feel that using CGM impacted the diabetes care overall on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better.
Measured: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Questionnaire responses regarding patient familiarity with continuous glucose monitoring
Questionnaire responses regarding patient familiarity with continuous glucose monitoring: regarding degree of familiarity of CGMs in general and the different types of information provided by CGMs, what is the subject's familiarity on a scale of 1-5, with 1=very unfamiliar, 2=unfamiliar, 3=neutral, 4=familiar, 5=very familiar.
Measured: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Secondary outcomes (3)
Degree of Average Change in Hemoglobin A1C from Start to End of Study
Degree of average change in Hemoglobin A1C from start to end of study
Measured: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Degree of Average Change in Glucose Management Indicator (GMI)
Degree of average change in glucose management indicator (GMI)
Measured: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Number of Participants with 30-day Readmissions Related to Glycemic Control
Number of participants with 30-day Readmissions Related to Glycemic Control (hyperglycemia, hypoglycemia, or diabetic ketoacidosis)
Measured: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2025
- Study start9 Mar 2025
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 Diabetes Mellitus (T2DM)Studies of the same condition, open and under way.
- More trials run by Vanderbilt University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vanderbilt University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Angel Morvant, Vanderbilt University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06852950
- Sponsor's protocol ID
- 242071
- Status last verified
- Mar 2026
- First submitted
- 20 Feb 2025
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
- ClinicalTrials.gov ID
- NCT06852950
- Acronym / sponsor ID
- 242071
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Vanderbilt University Medical CenterUniversity, hospital or other
- Study start
- 9 Mar 2025 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 28 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Libre 3 Plus Continuous Glucose Monitor | Experimental | Device: Libre 3 Plus Continuous Glucose MonitorSubjects in this arm will start using the Libre 3 Plus continuous glucose monitor. |
| Dexcom G7 Continuous Glucose Monitor | Experimental | Device: Dexcom G7 Continuous Glucose MonitorSubjects in this arm will start using the Dexcom G7 continuous glucose monitor. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
- Able to give informed consent
- Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
- POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
- Need glucose readings greater than or equal to one time per day
Key exclusion criteria (12 listed)
- Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
- Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
- Received chemotherapy during current hospitalization
- Planning on major surgery within 10-15 days
- Hemodialysis or peritoneal dialysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Libre 3 Plus Continuous Glucose MonitorSubjects in this arm will start using the Libre 3 Plus continuous glucose monitor. | Device | Libre 3 Plus Continuous Glucose Monitor |
| Dexcom G7 Continuous Glucose MonitorSubjects in this arm will start using the Dexcom G7 continuous glucose monitor. | Device | Dexcom G7 Continuous Glucose Monitor |
Primary outcome
Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system: regarding how do subjects feel that using CGM impacted their glucose control on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better?; regarding what is the overall opinion of subject's experience with CGM use on a scale of 1-5, with 1=very negative, 2=negative, 3=neutral, 4=positive, 5=very positive.
Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care: regarding how do subjects feel that using CGM impacted the diabetes care overall on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better.
Questionnaire responses regarding patient familiarity with continuous glucose monitoring
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Questionnaire responses regarding patient familiarity with continuous glucose monitoring: regarding degree of familiarity of CGMs in general and the different types of information provided by CGMs, what is the subject's familiarity on a scale of 1-5, with 1=very unfamiliar, 2=unfamiliar, 3=neutral, 4=familiar, 5=very familiar.
3 secondary outcomes
Degree of Average Change in Hemoglobin A1C from Start to End of Study
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Degree of Average Change in Glucose Management Indicator (GMI)
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Number of Participants with 30-day Readmissions Related to Glycemic Control
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Type 2 Diabetes Mellitus (T2DM)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 2
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
RecruitingPhase 3
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Obesity, Overweight
RecruitingObservational study
Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes
T2DM (Type 2 Diabetes Mellitus)
Active, not recruitingObservational study
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Libre 3 Plus Continuous Glucose Monitor and Dexcom G7 Continuous Glucose Monitor in people with Type 2 Diabetes Mellitus (T2DM) and Type 1 Diabetes Mellitus (T1DM), run by Vanderbilt University Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Angel Morvant, MD (615-343-8332, angel.morvant@vumc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system (time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.